Search PubMed⌕ Search

PubMed · 10495458

Examining the minimum important difference.

Abstract

The increasing use of constructed scales and indices in clinical science has preceded in many cases a clear understanding of how to appraise the importance of the differences or changes that are thereby observed. For example, in the design of clinical trials which employ such scales as outcome measures it may be difficult to specify what constitutes a clinically significant shift in means, a key factor in sample size calculations. Determination of the minimum important difference relative to specific outcome measures has historically been based on informal and/or intuitive arguments. In this paper we propose a formal statistical framework for these considerations, based on a previously published validation study design which captures patients' perceptions in comparative self-reported assessments. We begin by adopting a mixed-effect model to represent the comparative assessments as composites of individual self-ratings on an underlying continuous scale. We then present two basic approaches for assessing the relation between the hypothesized latent scale and the outcome scale(s) under consideration, taking the latent scale as a plausible benchmark against which observable changes on the outcome scale can be judged.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R Brant, L Sutherland, R Hilsden. 1999-10-15. Examining the minimum important difference.. https://doi.org/10.1002/(sici)1097-0258(19991015)18%3A19%3C2593%3A%3Aaid-sim392%3E3.0.co%3B2-t

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Magnitude and quality of antibody response to a combination hepatitis A and hepatitis B vaccine.

Interference between antibodies generated by a combination hepatitis A and B vaccine was investigated by evaluating the quantity and quality of anti-hepatitis A virus (HAV) and anti-hepatitis B surface antigen (HBs) antibodies generated by Twinrix (Hepatitis A Inactivated and Hepatitis B (Recombinant) Vaccine). The magnitude of the immune response was determined by a retrospective analysis of eight clinical trials, completed during stepwise development of Twinrix. The functionality of anti-HAV was evaluated by comparison of routine ELISA results with neutralization assays and was further characterized by defining the epitope-specificity of binding. Functionality of the anti-HBs response was not tested because a validated assay was not developed at the time this study was conducted. Results of all analyses demonstrated that the combination vaccine induced high antibody titers against hepatitis A and B and a functional anti-HAV response, with no evidence of immune interference to either viral antigen.

Clinical Trials as Topic↗

Allocation of subjects to test null relative risks smaller than one.

Allocating a proportion k'=1/(1+ radicalr(0)) of subjects to an intervention is a practical approach to approximately maximize power for testing whether an intervention reduces relative risk of disease below a null ratio r(0)<1. Furthermore, allocating k'(s), a convenient fraction close to k', to intervention performs nearly as well; for example, allocating k'(s)=3/5 for 0.5> or =r(0)>0.33,2/3 for 0.33> or =r(0)>0.17 and 3/4 for 0.17> or =r(0)> or =0.10. Both k' and k'(s) are easily calculated and invariant to alterations in disease rate estimates under null and alternative hypotheses, when r(0) remains constant. In examples that we studied, allocating k' (or k'(s)) subjects to intervention achieved close to the minimum possible sample size, given test size and power (equivalently, maximum power, given test size and sample size), for likelihood score tests. Compared to equal allocation, k' and k'(s) reduced sample sizes by amounts ranging from approximately 5.5 per cent for r(0)=0.50 to approximately 24 per cent for r(0)=0.10. These sample size savings may be particularly important for large studies of prophylactic interventions such as vaccines. While k' was derived from variance minimization for an arcsine transformation, we do not recommend the arcsine test, since its true size exceeded the nominal value. In contrast, the true size for the uncorrected score test was less than the nominal size. A skewness correction made the size of the score test very close to the nominal level and slightly increased power. We recommend using the score test, or the skewness-corrected score test, for planing studies designed to show a ratio of proportions is less than a prespecified null ratio r(0)<1.

Clinical Trials as Topic↗

A three-stage clinical trial design for rare disorders.

Many clinical trials of uncommon diseases are underpowered because of the difficulty of recruiting adequate numbers of subjects. We propose a clinical trial design with improved statistical power compared to the traditional randomized trial for use in clinical trials of rare diseases. The three-stage clinical trial design consists of an initial randomized placebo-controlled stage, a randomized withdrawal stage for subjects who responded, and a third randomized stage for placebo non-responders who subsequently respond to treatment. Test level and power were assessed by computer-intensive exact calculations. The three-stage clinical trial design was found to be consistently superior to the traditional randomized trial design in all cases examined, with sample sizes typically reduced by 20 per cent to 30 per cent while maintaining comparable power. When a treatment clearly superior to placebo was considered, our design reached a power of 75 per cent with a sample of 21 patients compared with the 52 needed to attain this power when only a randomized controlled trial was used. In situations where patient numbers are limited, a three-stage clinical trial design may be a more powerful design than the traditional randomized trial for detecting clinical benefits.

Clinical Trials as Topic↗